GRYT Health and BMS launch COVID-19 Advocacy Exchange

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GRYT Health and Bristol Myers Squibb Co. developed the COVID Advocacy Exchange, a virtual platform to connect patient advocacy organizations, patients, policy makers, healthcare practitioners, and industry in the exchange of information.

The COVID Advocacy Exchange will invite close to 100 global and local advocacy organizations, spanning disease states, to virtually meet and support patients with serious diseases while navigating the current COVID-19 pandemic. The virtual platform will provide access to data and information, as well as the opportunity to participate in weekly live, interactive sessions to foster discussion and collaboration.

The virtual platform will provide advocacy organizations and patients with access to materials and information offering support across the following disease areas: oncology, cardiovascular, immunology & fibrosis, hematology and multiple sclerosis. Participants will have access to materials from Bristol Myers Squibb, other advocacy organizations and third-party experts, including curated best practices, white papers, peer-reviewed articles and multimedia content addressing the unique advocacy challenges associated with the COVID-19 pandemic for advocates and patients. Resources to address digital fundraising and other issues exacerbated by the pandemic will also be available.

Exhibitor information and the first weekly live, interactive session will be available here, launching the week of May 18. To register for free access to the platform and the series, visit www.covidadvocacyexchange.com.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login